CPRX vs. FLGT
Compare and contrast key facts about Catalyst Pharmaceuticals, Inc. (CPRX) and Fulgent Genetics, Inc. (FLGT).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CPRX or FLGT.
Correlation
The correlation between CPRX and FLGT is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
CPRX vs. FLGT - Performance Comparison
Loading data...
Key characteristics
CPRX:
1.19
FLGT:
-0.21
CPRX:
1.95
FLGT:
0.04
CPRX:
1.22
FLGT:
1.00
CPRX:
1.65
FLGT:
-0.10
CPRX:
6.46
FLGT:
-0.39
CPRX:
7.40%
FLGT:
22.38%
CPRX:
41.35%
FLGT:
46.32%
CPRX:
-94.25%
FLGT:
-91.69%
CPRX:
-5.32%
FLGT:
-88.93%
Fundamentals
CPRX:
$2.97B
FLGT:
$619.53M
CPRX:
$1.57
FLGT:
-$1.33
CPRX:
0.00
FLGT:
1.32
CPRX:
5.56
FLGT:
2.12
CPRX:
3.65
FLGT:
0.55
CPRX:
$534.65M
FLGT:
$292.45M
CPRX:
$441.72M
FLGT:
$111.47M
CPRX:
$250.28M
FLGT:
-$47.19M
Returns By Period
In the year-to-date period, CPRX achieves a 16.77% return, which is significantly higher than FLGT's 10.18% return.
CPRX
16.77%
8.21%
18.30%
47.79%
40.03%
19.87%
FLGT
10.18%
13.94%
17.56%
-7.96%
3.47%
N/A
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
CPRX vs. FLGT — Risk-Adjusted Performance Rank
CPRX
FLGT
CPRX vs. FLGT - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Fulgent Genetics, Inc. (FLGT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
CPRX vs. FLGT - Dividend Comparison
Neither CPRX nor FLGT has paid dividends to shareholders.
Drawdowns
CPRX vs. FLGT - Drawdown Comparison
The maximum CPRX drawdown since its inception was -94.25%, roughly equal to the maximum FLGT drawdown of -91.69%. Use the drawdown chart below to compare losses from any high point for CPRX and FLGT. For additional features, visit the drawdowns tool.
Loading data...
Volatility
CPRX vs. FLGT - Volatility Comparison
The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 10.00%, while Fulgent Genetics, Inc. (FLGT) has a volatility of 21.64%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than FLGT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
CPRX vs. FLGT - Financials Comparison
This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and Fulgent Genetics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CPRX vs. FLGT - Profitability Comparison
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a gross profit of 123.51M and revenue of 141.42M. Therefore, the gross margin over that period was 87.3%.
FLGT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Fulgent Genetics, Inc. reported a gross profit of 28.35M and revenue of 73.46M. Therefore, the gross margin over that period was 38.6%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported an operating income of 63.37M and revenue of 141.42M, resulting in an operating margin of 44.8%.
FLGT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Fulgent Genetics, Inc. reported an operating income of -11.90M and revenue of 73.46M, resulting in an operating margin of -16.2%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a net income of 56.74M and revenue of 141.42M, resulting in a net margin of 40.1%.
FLGT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Fulgent Genetics, Inc. reported a net income of -11.53M and revenue of 73.46M, resulting in a net margin of -15.7%.